Want to see IN:WANBURY full AI Analyst Report?
WANBURY Stock Chart & Stats
₹235.40
-₹13.70(-4.99%)
At close: 4:00 PM EST
₹235.40
-₹13.70(-4.99%)
Day’s Range― - ―
52-Week Range₹162.00 - ₹316.60
Previous CloseN/A
Volume54.35K
Average Volume (3M)8.26K
Market Cap
₹10.03B
Enterprise Value₹11.53B
Total Cash (Recent Filing)₹76.32M
Total Debt (Recent Filing)₹2.24B
Price to Earnings (P/E)14.0
Beta2.09
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)20.48
Shares Outstanding34,939,400
10 Day Avg. Volume8,584
30 Day Avg. Volume8,255
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)4.96
Price to Sales (P/S)1.10
P/FCF Ratio-12.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)24.6
Revenue Forecast (FY)₹8.76B
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendSustained top-line growth since FY2023 and a year-over-year increase into FY2026 indicate expanding product uptake and market penetration. Durable revenue expansion supports scale economics, long-term R&D or capacity investments, and reduces reliance on one-off gains over the next 2–6 months.
Profitability TurnaroundA clear shift from loss to solid operating and net margins by FY2026 reflects structural improvements in pricing, cost control or product mix. Durable profitability enhances internal funding capacity and resilience to industry cyclicality, lowering the need for frequent external financing over the medium term.
Balance Sheet RepairRe-establishing positive equity and expanding it across FY2024–FY2026 signals meaningful capital restoration. A repaired equity base improves creditor confidence and access to capital for strategic investments, making the company structurally better positioned for growth or opportunistic M&A over coming months.
Bears Say
Weak Cash ConversionEarnings not converting to cash creates durable funding vulnerability: negative free cash flow across FY2025–FY2026 forces reliance on external financing or equity, constrains reinvestment, and raises execution risk if working capital or capex remains high in the next several quarters.
Elevated LeverageDebt exceeding equity with a ~1.6x debt-to-equity ratio leaves the company exposed to refinancing and interest-rate risk. Elevated leverage reduces financial flexibility, increases fixed costs, and amplifies earnings volatility impacts, limiting strategic optionality over the medium term.
Margin VolatilitySignificant and inconsistent margin swings, including gross margin compression into FY2026, point to unstable cost structure or pricing pressure. This reduces earnings predictability and complicates long-term planning for investment, pricing strategy, and competitor responses over the next several quarters.
Wanbury Limited News
WANBURY FAQ
What was Wanbury Limited’s price range in the past 12 months?
Wanbury Limited lowest stock price was ₹162.00 and its highest was ₹316.60 in the past 12 months.
What is Wanbury Limited’s market cap?
Wanbury Limited’s market cap is ₹10.03B.
When is Wanbury Limited’s upcoming earnings report date?
Wanbury Limited’s upcoming earnings report date is Aug 06, 2026 which is in 31 days.
How were Wanbury Limited’s earnings last quarter?
Wanbury Limited released its earnings results on May 29, 2026. The company reported ₹6.2 earnings per share for the quarter, beating the consensus estimate of N/A by ₹6.2.
Is Wanbury Limited overvalued?
According to Wall Street analysts Wanbury Limited’s price is currently Overvalued.
Does Wanbury Limited pay dividends?
Wanbury Limited pays a Notavailable dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Wanbury Limited dividends here
What is Wanbury Limited’s EPS estimate?
Wanbury Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wanbury Limited have?
Wanbury Limited has 34,939,400 shares outstanding.
What happened to Wanbury Limited’s price movement after its last earnings report?
Wanbury Limited reported an EPS of ₹6.2 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.31%.
Which hedge fund is a major shareholder of Wanbury Limited?
Currently, no hedge funds are holding shares in IN:WANBURY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wanbury Limited
Wanbury Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and commercialization of both finished drug products (formulations) and active pharmaceutical ingredients (APIs). The company's diverse range of formulations addresses numerous therapeutic areas, including women's health, bone and joint conditions, hematological disorders, diabetes management, nutritional support, gastrointestinal ailments, post-stroke recovery, infectious diseases, respiratory issues, inflammatory conditions, pain relief, and general medicine, marketed under approximately 70 different brands. Additionally, Wanbury supplies APIs vital for medicines treating diabetes, pain, depression, allergies, inflammation, arthritis, thrombosis, epilepsy, and hypertension. The company extends its reach beyond India through product exports. Originally incorporated in 1988 as Pearl Organics Limited, the firm was rebranded as Wanbury Limited in 2004 and maintains its corporate headquarters in Navi Mumbai, India.
Technical Analysis
Jagsonpal Pharmaceuticals Ltd.
―
Kilitch Drugs (India) Limited
―
Lincoln Pharmaceuticals Ltd
―
Zim Laboratories Ltd.
―
Anuh Pharma Limited
―